TOP > 外国特許検索 > MUCOSAL VACCINE COMPOSITION FOR BOVINE MASTITIS

MUCOSAL VACCINE COMPOSITION FOR BOVINE MASTITIS

外国特許コード F200010058
整理番号 6099
掲載日 2020年5月15日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2019JP030451
国際公開番号 WO 2020027318
国際出願日 令和元年8月2日(2019.8.2)
国際公開日 令和2年2月6日(2020.2.6)
優先権データ
  • 特願2018-147175 (2018.8.3) JP
発明の名称 (英語) MUCOSAL VACCINE COMPOSITION FOR BOVINE MASTITIS
発明の概要(英語) A mucosal vaccine composition for preventing bovine mastitis, which comprises: an antigen originated from Staphylococcus aureus; and a nano gel comprising a polysaccharide having a cationic functional group and a hydrophobic functional group in side chains thereof. When the composition is administered to a cow, the titer of an antibody against Staphylococcus aureus increases immediately after the contact with the bacterium in the breast of the cow. Therefore, the composition can prevent the occurrence of mastitis in the cow.
従来技術、競合技術の概要(英語) BACKGROUND ART
Mastitis is, bacteria from the mouth entering the nipple of the breast and the mammary gland, mammary gland by repeating the growth and fixing, mammary gland cells from being damaged in inflammation, infectious disease.
Mastitis is dairy, milk production throughout the world including Japan occurs in the field, the higher its occurrence frequency. Suffering from breast milk cow is, quality and amount is lowered. In addition, treatment with antibiotics for mastitis usually are performed, during the treatment period of milk remaining in the antibiotic, cannot be shipped. Moreover, is treated with antibiotics do is when, not economically viable for cattle handling and waste, disposal may be leading. Therefore, mastitis is, the major cause of economic loss in the dairy industry and, as a result of preventing the development is in strong demand.
Mastitis is, various bacterial species is caused by the complex disease, in their bacterial species, Staphylococcus aureus (Staphylococcus aureus, S. aureus) is the most common. Therefore, for the purpose of prevention of mastitis, bacterial vaccines and the target have been developed (Patent Document 1).
Has been already, (registered trademark, manufactured by HIPRA) STARTVAC, (registered trademark, manufactured by Boehringer Ingelheim) or the like Lysigin, vaccines and the target S. aureus, have been commercially available.
However, most of these muscle injection type vaccine, serum IgG antibody titer in an increased, contributing to the protection of non-bacterial infection (such as IgA) IgG antibody titer in the mammary gland does not increase, is not sufficiently able to induce cellular immune response.
In addition, S. aureus, an extremely early stage mammary epithelial cells to invade into the, as a result, the bacteria antibodies immunologically state becomes less vulnerable to attack.
Therefore, in the mammary gland from S. aureus such as IgA antibody titer immediately upon contact with the enhanced, the microbial infection can be effectively suppressed has been desired the development of vaccines.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NATIONAL AGRICULTURE AND FOOD RESEARCH ORGANIZATION
  • KYOTO UNIVERSITY
  • TOHOKU UNIVERSITY
  • 発明者(英語)
  • HAYASHI Tomohito
  • KIKU Yoshio
  • NAGASAWA Yuya
  • AKIYOSHI Kazunari
  • SAWADA Shin-ichi
  • ASO Hisashi
  • NOCHI Tomonori
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記までご連絡ください。

PAGE TOP

close
close
close
close
close
close